Chrysanthemum has several active ingredients that can potentially treat dry eye by inhibiting inflammation-related factors and pathways, thus reducing inflammation of lacrimal gland tissue.
Network Pharmacology Chrysanthemum Dry Eye
The study used network pharmacology methods and various databases to further analyze the mechanism of Chrysanthemum in treating dry eye. First, the TCMSP was used to screen for candidate active ingredient molecules of chrysanthemum showcasing requisite oral bioavailability and drug similarity. The active ingredients of chrysanthemum were then identified, followed by target prediction. Cytoscape was used to construct a compound-target network for chrysanthemum. The Online Mendelian Inheritance in Man and DisGeNET databases were utilized to pinpoint pathogenic genes associated with dry eye, and the STRING database produced an interaction network and bar graph to scrutinize protein interactions. Using Venny, a final drug-active ingredient-key target-disease network was created.
The study found that Chrysanthemum has eighty active ingredients corresponding to targets for treating dry eye. These key functional targets primarily regulate gene expression, oxidative stress, immune response, apoptosis, proliferation, regulation of cellular inflammation-related factors, and angiogenesis. The primary pathways associated with these key targets include interleukin signaling, metabolism, cytokine signaling in the immune system, immune system, and signal transduction, thereby improving the condition of dry eye primarily through the inhibition of inflammation-related factors.
View Article